Brief: Incannex Announces Final Results From Phase 1 Clinical Trial Assessing Safety And Pharmacokinetics Of IHL-675A
02/05/2023 12:36
May 2 (Reuters) - Incannex Healthcare Ltd IHL.AX :
* INCANNEX ANNOUNCES FINAL RESULTS FROM PHASE 1 CLINICAL
TRIAL
ASSESSING SAFETY AND PHARMACOKINETICS OF IHL-675A
* INCANNEX HEALTHCARE LTD - IHL-675A WAS WELL TOLERATED,
WITH NO
ADVERSE EVENTS OF CONCERN AND NO SERIOUS ADVERSE EVENTS REPORTED
* INCANNEX HEALTHCARE LTD - SAME NUMBER OF TREATMENT RELATED
TREATMENT EMERGENT ADVERSE EVENTS (TEAES) WERE REPORTED FOR
IHL-675A AS FOR EPIDIOLEX
* INCANNEX HEALTHCARE LTD - ALL TEAES WERE MINOR WITH
EXCEPTION OF
ONE INCIDENCE OF MODERATE SEVERITY ABDOMINAL CRAMPS WHICH
RESOLVED SOON AFTER ON SET
* INCANNEX HEALTHCARE LTD - CO HAS FILED A REQUEST FOR
PRE-IND
MEETING ON DEVELOPMENT OF IHL-675A FOR TREATMENT OF ARTHRITIS
WITH FDA
Source text for Eikon: ID:nGNXx6Dmq
Further company coverage: IHL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed